Cargando…
Immunotherapy of hepatocellular carcinoma: recent progress and new strategy
Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment, represented by immune checkpoint inhibitors (ICIs), which aim to improve the immune system’s ability to recognize, ta...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206122/ https://www.ncbi.nlm.nih.gov/pubmed/37234162 http://dx.doi.org/10.3389/fimmu.2023.1192506 |
_version_ | 1785046158149681152 |
---|---|
author | Li, Jiarui Xuan, Shihai Dong, Peng Xiang, Ze Gao, Ce Li, Mo Huang, Lan Wu, Jian |
author_facet | Li, Jiarui Xuan, Shihai Dong, Peng Xiang, Ze Gao, Ce Li, Mo Huang, Lan Wu, Jian |
author_sort | Li, Jiarui |
collection | PubMed |
description | Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment, represented by immune checkpoint inhibitors (ICIs), which aim to improve the immune system’s ability to recognize, target and eliminate cancer cells. The composition of the HCC immune microenvironment is the result of the interaction of immunosuppressive cells, immune effector cells, cytokine environment, and tumor cell intrinsic signaling pathway, and immunotherapy with strong anti-tumor immunity has received more and more research attention due to the limited responsiveness of HCC to ICI monotherapy. There is evidence of an organic combination of radiotherapy, chemotherapy, anti-angiogenic agents and ICI catering to the unmet medical needs of HCC. Moreover, immunotherapies such as adoptive cellular therapy (ACT), cancer vaccines and cytokines also show encouraging efficacy. It can significantly improve the ability of the immune system to eradicate tumor cells. This article reviews the role of immunotherapy in HCC, hoping to improve the effect of immunotherapy and develop personalized treatment regimens. |
format | Online Article Text |
id | pubmed-10206122 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102061222023-05-25 Immunotherapy of hepatocellular carcinoma: recent progress and new strategy Li, Jiarui Xuan, Shihai Dong, Peng Xiang, Ze Gao, Ce Li, Mo Huang, Lan Wu, Jian Front Immunol Immunology Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment, represented by immune checkpoint inhibitors (ICIs), which aim to improve the immune system’s ability to recognize, target and eliminate cancer cells. The composition of the HCC immune microenvironment is the result of the interaction of immunosuppressive cells, immune effector cells, cytokine environment, and tumor cell intrinsic signaling pathway, and immunotherapy with strong anti-tumor immunity has received more and more research attention due to the limited responsiveness of HCC to ICI monotherapy. There is evidence of an organic combination of radiotherapy, chemotherapy, anti-angiogenic agents and ICI catering to the unmet medical needs of HCC. Moreover, immunotherapies such as adoptive cellular therapy (ACT), cancer vaccines and cytokines also show encouraging efficacy. It can significantly improve the ability of the immune system to eradicate tumor cells. This article reviews the role of immunotherapy in HCC, hoping to improve the effect of immunotherapy and develop personalized treatment regimens. Frontiers Media S.A. 2023-05-10 /pmc/articles/PMC10206122/ /pubmed/37234162 http://dx.doi.org/10.3389/fimmu.2023.1192506 Text en Copyright © 2023 Li, Xuan, Dong, Xiang, Gao, Li, Huang and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Li, Jiarui Xuan, Shihai Dong, Peng Xiang, Ze Gao, Ce Li, Mo Huang, Lan Wu, Jian Immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
title | Immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
title_full | Immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
title_fullStr | Immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
title_full_unstemmed | Immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
title_short | Immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
title_sort | immunotherapy of hepatocellular carcinoma: recent progress and new strategy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206122/ https://www.ncbi.nlm.nih.gov/pubmed/37234162 http://dx.doi.org/10.3389/fimmu.2023.1192506 |
work_keys_str_mv | AT lijiarui immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT xuanshihai immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT dongpeng immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT xiangze immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT gaoce immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT limo immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT huanglan immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy AT wujian immunotherapyofhepatocellularcarcinomarecentprogressandnewstrategy |